Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

DSIP / Emideltide

DSIP is a nonapeptide historically called delta sleep-inducing peptide; endogenous identity and physiological role have been debated. A 16-person double-blind insomnia study found weak objective signals that could partly reflect placebo change and concluded major therapeutic benefit was unlikely.

Aliases reviewed
Delta sleep-inducing peptide, Emideltide
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
LimitedOne small double-blind study in 16 people.
Animal/cell
Not rated
Approved medicine
None foundScope: the Canadian and U.S. sources reviewed.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. Older work examined sleep architecture, stress-axis biomarkers, and neuroendocrine responses.

Identity

DSIP is a nonapeptide historically called delta sleep-inducing peptide; endogenous identity and physiological role have been debated.

Biological mechanism or research interest

Older work examined sleep architecture, stress-axis biomarkers, and neuroendocrine responses.

Verified approved human uses

No approved human use was verified in the reviewed Canadian or U.S. sources.

Investigational human evidence

A 16-person double-blind insomnia study found weak objective signals that could partly reflect placebo change and concluded major therapeutic benefit was unlikely.

Sleep restoration, stress reduction, pain control, and endocrine normalization are not established by the small, old studies.

Human versus animal or cell evidence

Animal and biomarker research does not resolve whether the peptide has a clinically useful sleep effect.

Limitations and known risks

FDA reports inadequate proposed-route safety information and potential peptide immunogenicity or impurity concerns; modern pharmacokinetic and long-term safety data are sparse.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.